Wipro Ltd. Executes on Its Growth Strategy

by | Feb 19, 2016 8:00 am | Managed Care, Private Equity | 0 comments

Acquiring, servicing and retaining customers is now a critical part of the health insurance business. That’s why global IT and business services company Wipro Limited (NYSE: WIT) agreed to pay $460 million for HealthPlan Services, a portfolio company of Water Street Healthcare Partners. HealthPlan Services offers a fully integrated business-process-as- a-service (BPaaS) solution to health insurance companies in the individual, group and ancillary markets. HealthPlan Services provides U.S. payers with a diversified portfolio of health insurance products delivered through its proprietary technology platform. It connects its payer clients to more than 40 public exchanges and more than... Read More »

IBM Watson Health Buys Truven Health Analytics

by | Feb 18, 2016 5:25 pm | eHealth, Private Equity | 0 comments

Big Healthcare Data just got bigger. IBM (NYSE: IBM) has spent some $4 billion in the past 12 months to build out its Watson Health division. The latest and largest deal is for Truven Health Analytics, for $2.6 billion. Truven Health provides cloud-based healthcare data, analytics and insights to more than 8,500 clients, including federal and state government agencies, health plans, hospitals, clinicians and life sciences companies. Veritas Capital is making a good $1.35 billion on the sale of Truven, which it acquired in 2012 for $1.25 billion, from Thomson Reuters Corp. (NYSE: TRI). Truven Health’s extensive data set will be integrated into IBM’s Watson Health Cloud, creating... Read More »

Mylan Bags Meda AB on the Second Try

by | Feb 18, 2016 8:00 am | Pharmaceuticals | 0 comments

The pharmaceutical M&A sector has gotten very quiet in February, with just five deals announced as of Feb. 17. Compared with the 11 announced in January 2016 and 13 announced in February 2015, deal making has definitely slowed down. So it was good news to hear that Mylan NV (NASDAQ: MYL) agreed to pay $9.9 billion, including debt, to acquire Swedish generic drug maker Meda AB (STO: MEDA). Back in 2014, when Mylan was still based in the United States and known as Mylan, Inc., it made an unsuccessful run at Meda. Of course, late last year it carried on an all-out hostile takeover battle for Perrigo Company (NYSE: PRGO) that proved unsuccessful in the end. This time around, the Meda... Read More »